about
Pasireotide: a novel treatment for patients with acromegalyUpdates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapiesCongress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Management of Patients With Nonfunctioning Pituitary Adenomas: Executive Summary.Factors associated with biochemical remission after microscopic transsphenoidal surgery for acromegaly.Diabetes insipidus, panhypopituitarism, and severe mental status deterioration in a patient with chordoid glioma: case report and literature review.Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review.Update on medical treatment for Cushing's disease.Medical management of Cushing's disease: what is the future?Successful treatment of sulfonylurea-induced prolonged hypoglycemia with use of octreotide.Second-line treatment for Cushing's disease when initial pituitary surgery is unsuccessful.New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapyMonitoring Patient Improvement Parameters following Pasireotide Treatment in Cushing's Disease.Relative adrenal insufficiency.Recent advances in the medical treatment of Cushing's disease.Acromegaly: a review of current medical therapy and new drugs on the horizon.Temozolomide for corticotroph pituitary adenomas refractory to standard therapy.Medical management of persistent and recurrent cushing disease.A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with mifepristone.The role of combination medical therapy in acromegaly: hope for the nonresponsive patient.Challenges and pitfalls in the diagnosis of hyperprolactinemia.Treatment of Cushing's disease: a mechanistic update.Acromegaly: assessing the disorder and navigating therapeutic options for treatment.Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers.Pituitary-directed medical therapy in Cushing's disease.Medical treatment of Cushing disease: new targets, new hope.Discovery of Cushing's Syndrome After Bariatric Surgery: Multicenter Series of 16 Patients.Update on adrenal insufficiency: diagnosis and management in pregnancy.The role of combination medical therapy in the treatment of acromegaly.Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline for Pretreatment Endocrine Evaluation of Patients With Nonfunctioning Pituitary Adenomas.AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: DIAGNOSIS OF RECURRENCE IN CUSHING DISEASE.EVALUATION AND MANAGEMENT OF ADRENAL INSUFFICIENCY IN CRITICALLY ILL PATIENTS: DISEASE STATE REVIEW.Recent Progress in the Medical Therapy of Pituitary TumorsCase Report: Reversible cabergoline-associated cardiac valvulopathy post drug discontinuationFRAX score in acromegaly: does it tell the whole story?Insight into cardiovascular risk factors in patients with acromegaly.Candida Meningitis After Transsphenoidal Surgery: A Single-Institution Case Series and Literature Review.Self-perception of cognitive function among patients with active acromegaly, controlled acromegaly, and non-functional pituitary adenoma: a pilot study.Dopamine agonist therapy induces significant recovery of HPA axis function in prolactinomas independent of tumor size: a large single center experience.Clinical profile of silent growth hormone pituitary adenomas; higher recurrence rate compared to silent gonadotroph pituitary tumors, a large single center experience.Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review.
P50
Q26774437-D61226F3-F3DA-4901-92E7-76B70D0012CBQ28076013-F1190933-B44D-4012-A678-C52D1D625648Q30275928-F9FFB318-C88A-42E9-B1B2-0B8AEAE7E792Q30408371-DB295FCA-65E1-49D7-A5DD-FF28F481BFEDQ33429762-35FD1D2B-9F05-4301-94D2-463F979305E5Q33772673-1B561B80-9322-4F21-B146-517DC7AE4915Q33802284-A0CF2729-F525-4C81-A5E4-60BA3F567506Q36236884-175253ED-61B9-428C-BE5E-4617348BCA01Q36710508-09E351D8-7C42-4ADD-BA7C-35E020917832Q36973140-40B734AF-A982-46BE-B52F-A63F6B59DA32Q37049132-13FF0BB3-B1C3-44E9-92D9-9FA5A556EB46Q37322951-6E2415E2-68B2-404A-9A86-1D7EF1346943Q37572316-D5570688-75E5-4A3D-A701-609818CB00D6Q37621524-D1438BC7-A44F-426A-BCDC-31A97403C1A6Q37795781-D72978AE-30C4-4E31-9DDF-BD09BCD7F492Q37802798-366877E4-14FA-45D0-A611-D7597392F222Q38049834-B06002C4-9D55-45B2-8016-78DBC37361BDQ38075650-16ADF4A9-69C9-49B1-AAAE-0EDE0A3B494EQ38117568-14A0E82D-1CCF-4C69-9B3F-849635E76CD9Q38204249-E4CC6754-E9EB-402B-B26F-68085EEB709DQ38240993-451B972C-416F-4168-8965-70FD10CCFB89Q38265480-44D49B60-2D30-4EA9-98B2-7BB22FBD021AQ38307934-9046C019-B8EA-45D6-8B24-86F0A4409A31Q38334659-E8E0192A-9A09-4544-A861-218C82B68B14Q38366909-D078285C-5720-4187-BC81-1A8728ECE9CDQ38445603-10A988B8-8056-48C0-A62B-0F6A3AADC42BQ38911225-CA7F132F-B478-4632-A730-DA62EAAC3FE7Q38927318-7DC33641-19DF-436E-858E-5B7CBAC2FFC0Q38956202-678BAAB0-D7D7-4C07-87AC-249EE7D07224Q38958468-D89518EA-6FA3-4FD1-A176-7ECD5058E5A8Q39195377-6D5D753A-1BD3-49A3-A6D1-EEB4C3E0EEC6Q39420116-EA45258C-D8B7-479D-84F2-626E512E77FFQ42792288-72CC3E66-4419-4FB9-9C69-9601D85B01CCQ43711038-6C57C1B9-B064-4193-8786-E9FBE64C9044Q44207353-987A0E73-03C4-4823-AE5A-D3F8A6BC28DDQ46315494-43B89B63-E5AF-4F78-A073-42A847CA30E8Q46320272-0C62EE43-5BE2-4527-8E95-1DBD5C02A064Q47266565-EDE65455-22BD-4CF6-A477-A09C42015BF3Q47606375-DDE180C8-76EB-40EF-9196-AC2305288F5AQ48186021-3A76A3C5-CF99-422B-AB86-E761876EA443
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Maria Fleseriu
@ast
Maria Fleseriu
@en
Maria Fleseriu
@es
Maria Fleseriu
@nl
type
label
Maria Fleseriu
@ast
Maria Fleseriu
@en
Maria Fleseriu
@es
Maria Fleseriu
@nl
prefLabel
Maria Fleseriu
@ast
Maria Fleseriu
@en
Maria Fleseriu
@es
Maria Fleseriu
@nl
P106
P21
P31
P496
0000-0001-9284-6289